期刊文献+

孤立性心房颤动患者血浆高敏C反应蛋白与大内皮素-1浓度变化及相互的关系 被引量:15

Relationship Between Plasma Levels of High-sensitivity C-reactive Protein and Big Endothelin-1 in Patients With Lone Atrial Fibrillation
下载PDF
导出
摘要 目的:探讨不同类型的孤立性心房颤动(房颤)患者血浆高敏C反应蛋白(hs-CRP)与大内皮素-1(big ET-1)的水平差异以及二者之间的关系。方法:入选我院128例纽约心脏协会心功能分级Ⅰ~Ⅱ级、左心室射血分数〉50%的孤立性房颤患者,其中阵发性房颤患者(阵发性房颤组)83例,持续性房颤患者(持续性房颤组)45例,同时选择年龄、性别及病情与之相匹配的阵发性事上性心动过速患者82例作为对照组,测定血浆hs—CRP及higET-1浓度并进行统计学分析。结果:①两组房颤患者血浆hs—CRP及hig ET-1浓度均高于对照组,差异有统计学意义(P〈0.05)。②持续性房颤组血浆hs—CRP浓度高于阵发性房颤组,差异有统计学意义(P〈0.05);持续性房颤组血浆higET-1浓度较阵发性房颤组有升高趋势,但差异无统计学意义(P〉0.05)。③在阵发性房颤组,血浆hs—CRP浓度与hig ET~1浓度呈正相关(s=0.563,P〈0.05);在持续性房颤组,血浆hs—CRP浓度与hig ET-1浓度有相关性(P〈0.05),但相关性较弱,r值〈0.1。结论:孤立性房颤患者血浆hs—CRP及hig ET-1浓度增加,且持续性房颤患者升高明显;阵发性孤立性房颤患者的血浆hs-CRP浓度big ET-1浓度呈正相关。 Objective: To explore the relationship between different levels of plasma high-sensitivity C-reactive protein (hs-CRP) and big endothelin-1 (big ET-1) in patients with different type of lone atrial ifbrillation (AF). Methods: A total of 128 lone AF patients with NYHA 1 to NYHA 11 and LVEF 〉 50% were divided into 2 groups: Paroxysmal AF group, n=83 and Persistent AF group, n=45. There was a Control group, containing 82 patients of paroxysmal supra ventricular tachycardia with the matched age and gender. Plasma levels of hs-CRP, big ET-1 were examined and compared among different groups. Results: (1) Compared with Control group, plasma levels of hs-CRP and big ET-1 were higher in both Paroxysmal and Persistent AF groups, P〈0.05. (2) Compared with Paroxysmal AF group, the patients in Persistent AF group showed the higher level of hs-CRP, P〈0.05, while the level of big ET-1 was similar between 2 AF groups, P〉0.05. (3) In Paroxysmal AF group, plasma level of hs-CRP was positively related to ET-1 (F0.563, P〈0.05), and in Persistent AF group, hs-CRP was weakly related to ET-1 (r〈0. 1). Conclusion: Lone AF patients have elevated plasma levels of hs-CRP and big ET-1, such elevation is more obvious in persistent AF patients; plasma level of hs-CRP is positively related to big ET-1 in paroxysmal lone AF patients.
出处 《中国循环杂志》 CSCD 北大核心 2015年第3期240-243,共4页 Chinese Circulation Journal
关键词 心房颤动 炎症 高敏C反应蛋白 大内皮素-1 BIG ENDOTHELIN-1 Atrial ifbrillation Inlfammation High-sensitivity C-reactive protein
  • 相关文献

参考文献22

  • 1Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation. Circulation, 1996, 93: 1262-1277.
  • 2Aviles R J, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation, 2003, 108: 3006-3010.
  • 3Kourliouws A, Savelieva I, Kiotsekoglou A, et al. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J, 2009, 157: 243- 252.
  • 4Watts SW, Thakali K, Smark C, et al. Big ET-I processing into vasoactive peptides in arteries and veins. Vascul Pharmacol, 2007, 47: 302-312.
  • 5Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 1997, 96: 1180-1184.
  • 6Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile periearditis model. Cardiovasc Res, 2004, 62:105-111.
  • 7Bruins P, te Vehhuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation, 1997, 96: 3542-3548.
  • 8Malouf JF, Kanagala R, A1 AF, et al. High sensitivity C-reactive protein: A novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coil Cardiol, 2005, 46: 1284-1287.
  • 9Lin YJ, Tsao HM, Chang SL, et al. Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation. Am J Cardiol, 2010, 105: 495-501.
  • 10Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J, 2004, 45: 441-445.

二级参考文献32

  • 1中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3046
  • 2Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J, 2004, 25: 1100-1107.
  • 3Conway DS, Buggins P, Hughes E, et al. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol, 2004, 43: 2075-2082.
  • 4Watanabe T, Takeishi Y, Hirono O, et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels, 2005, 20: 45-49.
  • 5Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation, 2003, 108: 3006-3010.
  • 6Torres JL, Ridker PM. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curt Opin Cardid, 2003,18: 471-478.
  • 7Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation, 2001, 104: 2886-2891.
  • 8Demellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol, 2001, 56: 375-380.
  • 9Conway DS, Buggins P, Hughes E, et al. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol, 2004, 94: 508-510.
  • 10Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J, 2004, 45: 441-445.

共引文献19

同被引文献124

  • 1尚冬升,边云飞,杨慧宇,杨慧月,李小雷.脂联素在高血压致炎症和心肌纤维化中的作用[J].中国动脉硬化杂志,2015,23(5):464-468. 被引量:4
  • 2胡亚美,江载芳.诸福棠实用儿科学[M].7版.北京:人民卫生出版社,2003:485.
  • 3Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coil Cardiol, 2014, 63: 2335-2345.
  • 4Lewicka E, Dudzinska-Gehrmann J, Dabrowska-Kugacka A, et al. Neurohumoral factors as markers of recurrence of atrial fibrillation examined in patients with dual-chamber pacemaker. Int J Cardiol, 2014, 175: 213-214.
  • 5Zakeri R, Bodaug BA, McNuhy SE, et al. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail, 2014, 7: 123-130.
  • 6Mayyas F, Niebauer M, Zurick A, et al. Association of left atrial endothelin-I with atrial rhythm, size, and fibrosis in patients with structural heart disease. Circ Arrhythm Electrophysiol, 2010, 3: 369- 379.
  • 7Leask A. Potential therapeutic targets for cardiac fibrosis: TGFheta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res, 2010, 106: 1675-1680.
  • 8Jaffer FE, Knauss TC, Poptic E, et al, Endothelin stimulates PDGF secretion in cultured human mesangial cells. Kidney Int, 1990, 38: 1193-1198.
  • 9Wakili R, Voigt N, Kaab S, et al. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest, 2011, 121: 2955- 2968.
  • 10Syed H, Sara R, Chidlow G, et al. Sulfisoxazole, an endothelin receptor antagonist, protects retinal neurones from insults of ischemia/ reperfusion or lipopolysaccharide. Neurochem Int, 2006, 48: 708-717.

引证文献15

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部